Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook

Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook

Submitted by admin on April 6, 2018 - 11:49am
Source: 
Fierce Pharma
News Tags: 
Merck
Pfizer
immuno-oncology
M&A
Keytruda
Prevnar
Ibrance
Xeljanz
Xtandi
Headline: 
Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook

Do Not Allow Advertisers to Use My Personal information